When a person has too many CAGs in a row near
the start of the huntingtin gene, a harmful «mutant» form of the protein is produced based on the instructions in the gene.
Not exact matches
2015 will see the
start of the first human clinical trial
of a gene silencing or
huntingtin - lowering drug, which specifically aims to reduce production
of mutant
huntingtin in the brains
of HD patients.
Normally, neurons
start life deep within the developing brain, migrate out to the surface and then make a network
of connections with others, but Sandrine Humbert's group showed that those without
huntingtin get stuck, never making it to where they need to go.
The expanded CAG sequence in the HD gene results in a
huntingtin protein with too many glutamines at the
start of it.
There are many ways
of achieving the goal
of lowering mutant
huntingtin, expected to
start new trials soon or already in early trials.